Caritas Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Caritas Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $7.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Caritas Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $7.2M Trade | TransData Nexus

Caritas Healthcare Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $7.2M Total Trade · DGFT Verified

Caritas Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $7.2M across 9 products in 6 therapeutic categories. Based on 150 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Tacrolimus ($1.7M), Carvedilol ($1.4M), Methylprednisolone ($1.1M).

Caritas Healthcare Private Limited — Export Portfolio & Destination Treemap

Caritas Healthcare Private Limited pharmaceutical export portfolio — 9 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Caritas Healthcare Private Limited? — Company Overview & Market Position

Caritas Healthcare Private Limited, established on December 10, 2012, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24232GJ2012PTC072938. Its authorized capital stands at ₹5.00 crore, with a paid-up capital of ₹3.01 crore. As of the latest available data, Caritas Healthcare employs approximately 17 professionals. The company's registered office is located at B-902-905, Sankalp Iconic Tower, Opp. Vikram Nagar Nr. Iscon Cross Road, Iscon-Ambli Road, Ahmedabad, Gujarat, 380054. Caritas Healthcare specializes in the manufacturing and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

What Does Caritas Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tacrolimus$1.7M 2Carvedilol$1.4M

Product Portfolio — Top 9 by Export Value

Caritas Healthcare Private Limited exports 9 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tacrolimus	Immunosuppressants	$1.7M	34	0.8%	10
2	Carvedilol	Cardiovascular	$1.4M	29	1.5%	2
3	Methylprednisolone	Corticosteroids	$1.1M	22	3.8%	6
4	Rivaroxaban	Cardiovascular	$1.1M	22	2.1%	4
5	Amphotericin	Antifungals	$600.0K	12	0.7%	6
6	Chloroquine	Antimalarial & Antiparasitic	$523.4K	11	0.3%	10
7	Hydroxychloroquine	Antimalarial & Antiparasitic	$523.4K	11	0.4%	8
8	Fluorouracil	Oncology	$99.0K	6	0.8%	14
9	Digoxin	Cardiovascular	$66.7K	3	3.1%	6

Caritas Healthcare Private Limited exports 9 pharmaceutical products across 6 therapeutic categories with a total export value of $7.2M. The top category is Cardiovascular (36.5% of portfolio), followed by Immunosuppressants (23.7%), indicating a concentrated portfolio with the top 5 products accounting for 83.1% of total export value.

Caritas Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Caritas Healthcare operates manufacturing facilities that adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products. The company holds WHO-GMP certification, reflecting its commitment to global manufacturing excellence. While specific details regarding the locations and capacities of these facilities are not publicly disclosed, the company's adherence to international quality standards underscores its dedication to maintaining high manufacturing standards.

3Key Leadership

The leadership team at Caritas Healthcare Private Limited comprises:

Ketankumar Rameshbhai Patel: Director since December 10, 2012.

Avniben Ketanbhai Patel: Director since July 1, 2017.

These directors play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Caritas Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Caritas Healthcare Private Limited has made significant strides in entering and establishing a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has achieved approvals from major global regulatory authorities, such as the World Health Organization's Good Manufacturing Practice (WHO-GMP), the European Union's Good Manufacturing Practice (EU-GMP), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and Brazil's National Health Surveillance Agency (ANVISA). These certifications enable Caritas Healthcare to market its pharmaceutical products in these regions, ensuring compliance with stringent quality and safety standards. The company's adherence to these regulatory requirements underscores its commitment to delivering high-quality healthcare solutions globally.

2Emerging Markets

Caritas Healthcare Private Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification facilitates access to these regions, enabling it to supply pharmaceutical products that meet international quality standards. By leveraging its global certifications and manufacturing capabilities, Caritas Healthcare aims to address the growing healthcare needs in these developing markets, contributing to improved health outcomes and expanding its global presence.

Caritas Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Caritas Healthcare Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly disclosed. The company's WHO-GMP certification indicates compliance with international manufacturing standards, which is a prerequisite for entering regulated markets like the United States. However, without explicit FDA approvals or registrations, the company's ability to market its products in the U.S. remains unverified.

2WHO & EU GMP

Caritas Healthcare Private Limited holds certifications from the World Health Organization's Good Manufacturing Practice (WHO-GMP) and the European Union's Good Manufacturing Practice (EU-GMP). These certifications affirm the company's commitment to maintaining high manufacturing standards and ensuring the quality, safety, and efficacy of its pharmaceutical products. The WHO-GMP certification, in particular, facilitates access to various international markets by demonstrating compliance with globally recognized manufacturing practices.

3CDSCO & Indian Regulatory

Caritas Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Caritas Healthcare Private Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies across various therapeutic categories. While specific market share data for Caritas Healthcare's products is not publicly available, the company's diverse product portfolio and global certifications position it to compete effectively in the market. The company's focus on high-quality manufacturing, as evidenced by its WHO-GMP certification, provides a competitive edge in meeting the stringent requirements of regulated markets. Additionally, Caritas Healthcare's strategic expansion into emerging markets allows it to tap into growing healthcare needs, further enhancing its competitive positioning.

2Key Differentiators

Caritas Healthcare Private Limited distinguishes itself through its commitment to quality, as demonstrated by its WHO-GMP certification, and its strategic expansion into diverse geographic markets. The company's focus on high-quality manufacturing and adherence to international standards enable it to deliver pharmaceutical products that meet global expectations. Furthermore, Caritas Healthcare's presence in both regulated and emerging markets allows it to address a wide range of healthcare needs, enhancing its ability to serve diverse patient populations.

Strategic Position

Buyer Due Diligence Brief — Evaluating Caritas Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Caritas Healthcare Private Limited demonstrates a strong track record in pharmaceutical manufacturing, as indicated by its WHO-GMP certification. The company's export volume and consistency are supported by its strategic expansion into various international markets, including Africa, Latin America, and Southeast Asia. While specific reliability indicators are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a commitment to maintaining high standards in its operations.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance with international quality standards:

WHO-GMP Certification: Confirms adherence to the World Health Organization's Good Manufacturing Practice standards.

EU-GMP Certification: Indicates compliance with the European Union's Good Manufacturing Practice standards.

Frequently Asked Questions — Caritas Healthcare Private Limited

How many pharmaceutical products does Caritas Healthcare Private Limited export from India?

Caritas Healthcare Private Limited exports 9 pharmaceutical products across 6 therapeutic categories. The top exports are Tacrolimus ($1.7M), Carvedilol ($1.4M), Methylprednisolone ($1.1M), Rivaroxaban ($1.1M), Amphotericin ($600.0K). Total export value is $7.2M.

What is Caritas Healthcare Private Limited's total pharmaceutical export value?

Caritas Healthcare Private Limited's total pharmaceutical export value is $7.2M, based on 150 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Caritas Healthcare Private Limited cover?

Caritas Healthcare Private Limited exports across 6 therapeutic categories. The largest are Cardiovascular (36.5%, 3 products), Immunosuppressants (23.7%, 1 products), Corticosteroids (15.4%, 1 products).

Get Full Caritas Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.